Special Treatment Issues In Non-Small Cell Lung Cancer: Diagnosis And Management Of Lung Cancer
Publication Date: November 1, 2013
Recommendations
Pancoast Tumors
In patients with a Pancoast tumor, it is recommended that a tissue diagnosis be obtained prior to the initiation of therapy. (1, C)
307795
In patients with a Pancoast tumor being considered for curative-intent surgical resection, an MRI of the thoracic inlet and brachial plexus is recommended to characterize possible tumor invasion of vascular structures or the extradural space. (1, C)
307795
In patients with a Pancoast tumor being considered for curative resection, invasive mediastinal staging and extrathoracic imaging (head CT/MRI plus either whole-body PET or abdominal CT plus bone scan) are recommended. Involvement of mediastinal nodes and/or metastatic disease represent a contraindication to resection. (1, C)
307795
In patients with a potentially resectable Pancoast tumor (and good performance status), it is suggested that preoperative concurrent chemoradiotherapy is given prior to resection. (2, B)
307795
In patients undergoing resection of a Pancoast tumor, it is recommended that every effort be made to achieve a complete resection. (1, B)
307795
In patients undergoing resection of a Pancoast tumor, it is suggested that the resection consist of a lobectomy (instead of a nonanatomic wedge resection) as well as the involved chest wall structures. (2, C)
307795
In patients with an unresectable, but nonmetastatic Pancoast tumor who have good performance status, definitive concurrent chemotherapy and radiotherapy is suggested. (2, C)
307795
In patients with Pancoast tumors who are not candidates for curative-intent treatment, palliative radiotherapy is suggested. (2, B)
307795
Tumors Invading the Chest Wall
In patients with an NSCLC invading the chest wall who are being considered for curativeintent surgical resection, invasive mediastinal staging and extrathoracic imaging (head CT/MRI plus either whole-body PET or abdominal CT plus bone scan) are suggested. (2, C)
307795
In patients with an NSCLC invading the chest wall, involvement of mediastinal nodes and/or metastatic disease represent a contraindication to resection, and definitive chemoradiotherapy is suggested for these patients. (2, C)
307795
At the time of resection of a tumor invading the chest wall, it is recommended that every effort be made to achieve a complete resection. (1, B)
307795
T4 N0,1 M0 Tumors (Central Tumor With Direct Invasion)
In patients with a clinical T4 N0,1 M0 NSCLC being considered for curative resection, it is recommended that extrathoracic imaging (head CT/MRI plus either whole-body PET or abdominal CT plus bone scan) be undertaken. (1, C)
307795
In patients with a clinical T4 N0, M0 NSCLC without distant metastases being considered for curative resection, it is suggested that invasive mediastinal staging be undertaken. Involvement of mediastinal nodes represents a contraindication to primary resection. (2, C)
307795
In patients with a clinical T4 N0,1 M0 NSCLC being considered for curative resection, it is suggested that resection be undertaken only at a specialized center. (2, C)
307795
Additional Nodules and Multiple Primary Lung Cancers
In patients with two foci typical of a primary lung cancer (either proven or suspected, ie, solid, spiculated masses), it is suggested that identification of these as second primary lung cancers (SPLCs) (either synchronous or metachronous) should be based on the judgment of a multidisciplinary team, taking into account clinical, radiologic, and (if available) cytologic/histologic features. (2, C)
307795
In patients with two primary NSCLCs (synchronous or metachronous) being considered for curative surgical resection, invasive mediastinal staging and extrathoracic imaging (head CT/MRI plus either whole-body PET or abdominal CT plus bone scan) are recommended. (1, B)
307795
In patients (not suspected of having a second focus of cancer) who are found intraoperatively to have a second cancer in a different lobe, resection of each lesion is suggested, provided the patient has adequate pulmonary reserve and there is no N2 nodal involvement. (1, C)
307795
In patients with suspected or proven lung cancer and an additional (suspected) tumor nodule within the same lobe, it is recommended that no further diagnostic workup of the additional nodule is undertaken. (1, B)
307795
In patients with an additional (suspected) tumor nodule within the same lobe as a suspected or proven primary lung cancer, it is recommended that evaluation of extrathoracic metastases and confirmation of the mediastinal node status should be carried out as dictated by the primary lung cancer alone and not modified due to the presence of the additional lesion. (1, C)
307795
In patients with NSCLC and an additional focus of cancer within the same lobe (and no mediastinal or distant metastases), resection via a lobectomy is the recommended treatment. (1, B)
307795
In patients with suspected or proven lung cancer and an ipsilateral different lobe nodule(s), it is recommended that the judgment of a multidisciplinary team should reasonably exclude the possibility that this represents a benign lesion or a synchronous primary lung cancer, taking into account clinical, radiologic, and (if available) cytologic/histologic features. (1, C)
307795
In patients with an ipsilateral different lobe tumor nodule(s), it is suggested that evaluation for possible extrathoracic metastases (eg, PET and brain MRI/CT) should be carried out. (2, C)
307795
In patients with an ipsilateral different lobe tumor nodule(s), it is suggested that invasive evaluation to rule out mediastinal node involvement should be carried out. (2, C)
307795
In patients with NSCLC and an ipsilateral different lobe tumor nodule(s) (and no mediastinal or distant metastases), resection of each lesion is recommended, provided the patient has adequate pulmonary reserve. (1, B)
307795
In patients with a contralateral lobe tumor nodule(s), it is suggested that evaluation of extrathoracic metastases (eg, PET and brain MRI/CT) and invasive evaluation to rule out mediastinal node involvement should be carried out. (2, C)
307795
In patients with NSCLC and a contralateral lobe tumor nodule(s) (and no mediastinal or distant metastases), resection of each lesion is suggested, provided the patient has adequate pulmonary reserve. (2, C)
307795
In patients with multiple lesions that are at least partially ground glass and are suspected to be malignant, it is suggested that these are classified as multifocal lung cancer (MFLC). (2, C)
307795
In patients with suspected or proven MFLC who have a negative clinical evaluation and normal mediastinum by CT, it is suggested that distant and mediastinal staging are not routinely necessary. (2, C)
307795
In patients with suspected or proven MFLC, it is suggested that curative-intent treatment should be pursued. (2, C)
307795
In patients with suspected or proven MFLC, it is suggested that sublobar resection of all lesions suspected of being malignant be performed, if feasible. (2, C)
307795
Isolated Brain Metastasis
In patients with an isolated brain metastasis from NSCLC being considered for curative treatment, invasive mediastinal staging and extrathoracic imaging (either whole-body PET or abdominal CT plus bone scan) are suggested. (2, C)
307795
In patients with no other sites of metastases and a synchronous resectable N0,1 primary NSCLC, resection or radiosurgical ablation of an isolated brain metastasis is recommended (as well as resection of the primary tumor). (1, C)
307795
In patients with no other sites of metastases and a previously completely resected primary NSCLC ( metachronous presentation), resection or radiosurgical ablation of an isolated brain metastasis is recommended. (1, C)
307795
In patients who have undergone a curative resection of an isolated brain metastasis, adjuvant whole-brain radiotherapy (WBRT) is suggested. (2, B)
307795
In patients who have undergone a curative resection of an isolated brain metastasis, adjuvant chemotherapy is suggested. (2, B)
307795
Isolated Adrenal Metastasis
In patients with an isolated adrenal metastasis from NSCLC being considered for curativeintent surgical resection, invasive mediastinal staging and extrathoracic imaging (head CT/MRI plus either whole-body PET or abdominal CT plus bone scan) are suggested. (2, C)
307795
In patients with a synchronous resectable N0,1 primary NSCLC and an isolated adrenal metastasis, with no other sites of metastases, resection of the primary tumor and the adrenal metastasis is recommended. (1, C)
307795
In patients with no other sites of metastases and a previously completely resected primary NSCLC ( metachronous presentation), resection of an isolated adrenal metastasis is recommended. (1, C)
307795
In patients who have undergone a curative resection of an isolated adrenal metastasis, adjuvant chemotherapy is suggested. (2, B)
307795
Title
Special Treatment Issues In Non-Small Cell Lung Cancer: Diagnosis And Management Of Lung Cancer
Authoring Organization
American College of Chest Physicians
Publication Month/Year
November 1, 2013
External Publication Status
Published
Country of Publication
US
Document Objectives
This guideline updates the second edition and addresses patients with particular forms of non-small cell lung cancer that require special considerations, including Pancoast tumors, T4 N0,1 M0 tumors, additional nodules in the same lobe (T3), ipsilateral different lobe (T4) or contralateral lung (M1a), synchronous and metachronous second primary lung cancers, solitary brain and adrenal metastases, and chest wall involvement.
Target Patient Population
Patients with particular forms of non-small cell lung cancer
Inclusion Criteria
Female, Male, Adolescent, Adult, Older adult
Health Care Settings
Ambulatory, Hospital, Operating and recovery room, Outpatient, Radiology services
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Management, Treatment
Diseases/Conditions (MeSH)
D002289 - Carcinoma, Non-Small-Cell Lung, D008175 - Lung Neoplasms, D010178 - Pancoast Syndrome
Keywords
lung cancer, non-small cell lung cancer, Non Small Cell Lung Cancer, non_small_cell_lung_cancer
Methodology
Number of Source Documents
252
Literature Search Start Date
January 1, 2007
Literature Search End Date
January 1, 2012